PCRX
Pacira BioSciences, Inc.
Drug Manufacturers - Specialty & Generic · Healthcare · United States
36.39
close · 2026-10-29
value
70
cheaper than peers70
quality
55
stronger fundamentals55
ranked against
Drug Manufacturers - Specialty & Generic
value
quality
41 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 1.34× | 77 |
| price to book | 2.16× | 67 |
| EV to EBITDA | 9.97× | 61 |
| forward P/E | 10.52× | 55 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | 2.0% | 63 |
| debt to equity | 61.3% | 61 |
| revenue growth | 6.2% | 47 |
| operating margin | 6.2% | 46 |
4 of 4 measures available
Facts
| market cap | $1B |
| free cash flow | $92.8M |
| employees | 825 |
| first trade | 2011-02-03 |
| next earnings | 2026-08-04 |
| fundamentals updated | 2026-08-07 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 0.16 | -2.15 | 0.89 | 0.34 |
| free cash flow | $136.7M | $178.8M | $139.5M | $115.2M |
| net income | $7.0M | -$99.6M | $42.0M | $15.9M |
| revenue | $726.4M | $701.0M | $675.0M | $666.8M |
| unusual items | -$983,000 | -$155.7M | -$16.9M | $0 |